ReviewLeukemia2015

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

G Barosi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.